Defective C-propeptides of the Proα2(I) Chain of Type I Procollagen Impede Molecular Assembly and Result in Osteogenesis Imperfecta*

Received for publication, March 12, 2008 Published, JBC Papers in Press, March 27, 2008, DOI 10.1074/jbc.M801982200

James M. Pace1, Mary Wiese1, Andrea S. Drenguis1, Natalia Kuznetsova1, Sergey Leikin1, Ulrike Schwarze1, Diana Chen1, Suzanne H. Mooney1,2, Sheila Unger1, and Peter H. Byers1,3

From the 1Department of Pathology, University of Washington, Seattle, Washington 98195, the 2Section on Physical Biochemistry, NICHD, National Institutes of Health, Bethesda, Maryland 20892, the 3Institute of Human Genetics, University of Freiburg, Freiburg 79085, Germany, and the 4Department of Medicine, University of Washington, Seattle, Washington 98195

Type I procollagen is a heterotrimer composed of two proα1(I) chains and one proα2(I) chain, encoded by the COL1A1 and COL1A2 genes, respectively. Mutations in these genes usually lead to dominantly inherited forms of osteogenesis imperfecta (OI) by altering the triple helical domains, but a few affect sequences in the proα1(I) C-terminal propeptide (C-propeptide), and one, which has a phenotype only in homozygotes, alters the proα2(I) C-propeptide. Here we describe four dominant mutations in the COL1A2 gene that alter sequences of the proα2(I) C-propeptide in individuals with clinical features of a milder form of the disease, OI type IV. Three of the four appear to interfere with disulfide bonds that stabilize the C-propeptide conformation and its interaction with other chains in the trimer. Cultured cells synthesized proα2(I) chains that were slow to assemble with proα1(I) chains to form heterotrimers and that were retained intracellularly. Some alterations led to the uncharacteristic formation of proα1(I) homotrimers. These findings show that the C-propeptide of proα2(I), like that of the proα1(I) C-propeptide, is essential for efficient assembly of type I procollagen heterotrimers. The milder OI phenotypes likely reflect a diminished amount of normal type I procollagen, small populations of overmodified heterotrimers, and proα1(I) homotrimers that are compatible with normal skeletal growth.

Osteogenesis imperfecta (OI)4 (1, 2), commonly known as brittle bone disease, is usually caused by mutations in the COL1A1 and COL1A2 genes that encode the proα1(I) and proα2(I) chains, respectively, of type I procollagen. This heterotrimeric collagen is composed of two proα1(I) chains and one proα2(I) chain. Molecular assembly of the trimer is usually normal (14, 15). Therefore, the phenotype described by these mutations is thought to proceed without interruption, and thermal stability of the trimer is usually normal (14, 15). Therefore, the pheno-

* This work was supported, in whole or in part, by National Institutes of Health Grant 5R01AR041223-13. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Present address: Dept. of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030.

2 Present address: Epigenomics, Inc., Seattle, WA 98101.

3 To whom correspondence should be addressed: Dept. of Pathology, University of Washington, Box 357470, Seattle, WA 98195. Tel.: 206-543-4206; Fax: 206-616-1899; E-mail: pbyers@u.washington.edu.

4 The abbreviations used are: OI, osteogenesis imperfecta; C-propeptide; C-terminal propeptide; P, patient.

5 Database of Human Type I and Type III Collagen Mutations, The University of Leicester (available on the web).
**Experimental Procedures**

**Clinical Features of the Probands and Family Members**—Patient 1 (P1) was identified at 39 years of age because of multiple fractures (>40), all of which occurred in adulthood. He was 105 cm tall (≤ 5th centile), had normal scleral hue, and no evidence of dentinogenesis imperfecta. He was part of a family in which clinical characteristics of OI, including bone fractures, blue sclerae, and dentinogenesis imperfecta, had been noted in members of three generations among whom there was clinical heterogeneity (Fig. 1a and Table 1).

Patient 2 (P2) was identified in early childhood because of five fractures after minimal trauma. Further examination showed the presence of wormian bones in the skull and blue sclerae. At age 6 he was 117 cm tall (50th centile). His father had only one fracture by 33 years of age and had leg asymmetry and back pain. The proband’s two younger siblings both had blue sclerae. One also had back pain, whereas the other was born with club feet (Fig. 1b and Table 2).

Patient 3 (P3) was a 33-year-old woman who presented with severe osteoporosis. She had had at least 17 fractures, the first of which occurred at 8 years of age, mostly of the fingers, wrists, and toes. She was 162 cm tall (75th centile) with no alterations in scleral color, teeth, or hearing. Her father and brother each had sustained five or six fractures of ribs, fingers, and wrists.

Patient 4 (P4) was evaluated at 33 years of age because of multiple fractures. X-rays showed thin diaphyses and funneled metaphyses and overall decreased bone density. His teeth appeared somewhat translucent and his sclerae were white. He was 164 cm tall (5th centile). There was no family history of OI.

**Table 1**

Clinical Features of the Family Members of P1

| Individual | Age | Affected | Height (cm)/[percentile] | Number of fractures | Change in scleral hue | Dentinogenesis imperfecta |
|------------|-----|----------|--------------------------|---------------------|-----------------------|---------------------------|
| I-1        | 33  | NA       | 160 [5th]                | 0                   | NA                    | NA                        |
| I-2        | 2   | NA       | 153 [5th]                | 0                   | NA                    | NA                        |
| II-2       | NA  | +        | NA                       | 0                   | –                     | –                         |
| III-4      | 39  | +        | 160 [5th]                | 4–5                 | –                     | –                         |
| III-6      | 22  | –        | 173 [25th]               | 0                   | –                     | –                         |
| III-7      | 19  | –        | 173 [25th]               | 1                   | –                     | –                         |
| III-8      | 12  | –        | NA                       | 0                   | –                     | –                         |
| III-9      | 9   | +        | 134 [50th]               | 1                   | +                     | +                         |
| III-10     | 4   | +        | 103 [75th]               | 3                   | +                     | +                         |
| IV-1       | 8   | +        | NA                       | 2                   | +                     | +                         |
| IV-2       | 5   | +        | NA                       | 0                   | –                     | –                         |

* Individual designations are from pedigree (Fig. 1a).
* Age at clinical evaluation.
* NA, not available.
* Plus sign (+) denotes that the trait was present; minus sign (−) denotes that the trait was absent.
* Proband.

**Table 2**

Clinical Features of the Family Members of P2

| Individual | Age | Affected | Height (cm)/[percentile] | Number of fractures | Change in scleral hue | Other |
|------------|-----|----------|--------------------------|---------------------|-----------------------|-------|
| I-1        | 33  | +        | 172 [25th]               | 1                   | –                     | Leg asymmetry, back pain |
| I-2        | NA  | –        | 160 [25th]               | 0                   | –                     | Wormian bones            |
| II-1       | 6   | +        | 117 [50th]               | 5                   | +                     | Back pain                |
| II-2       | 8   | +        | 0                        | 0                   | +                     | Club feet                |
| II-3       | 1   | +        | 0                        | 0                   | –                     | –                         |

* Individual designations are from pedigree (Fig. 1b).
* Age at clinical evaluation.
* Plus sign (+) denotes that the trait was present; minus sign (−) denotes that the trait was absent.
* NA, not available.
* Proband.
Cell Culture and Metabolic Labeling of Proteins—Dermal fibroblast cultures were established from explanted skin biopsies of four OI patients (P1, P2, P3, and P4) and one normal individual (control) with appropriate consent. For each experiment, 250,000 cells were seeded into 35-mm dishes, incubated with ascorbic acid (50 μg/ml), and were proline-deprived prior to radiolabeling as described (19). For analysis of collagenous proteins, cells were incubated with 20 μCi of [3H]proline (Amersham Biosciences) for 18 h. To characterize hetero- and homotrimer populations, cells were incubated with 5 μCi of [14C]proline for 18 h. For pulse-chase studies, cells were incubated for 80 min with either 100 μCi of [3H]proline or 5 μCi of [14C]proline and then chased for indicated times with excess non-labeled proline as described (15).

Isolation and Analysis of Collagenous Proteins—Cell layer and medium fractions were collected separately, and proteins were ethanol-precipitated in the presence of protease inhibitors as detailed elsewhere (20). For pulse-chase analysis, 15 mM iodoacetamide (Sigma) was added to the cell fractions at the time of harvesting to prevent additional disulfide bond formation. To generate collagen-sized molecules, procollagen was partially digested with pepsin (19) to remove the propeptides. Samples were dissolved in SDS buffer, in some cases reduced with addition of dithiothreitol, and boiled for 3 min prior to separation by SDS-PAGE (3% stacking gel, pH 6.8, and 5% separating gel, pH 8.8). To separate unreduced trimers of type I procollagen, a lower percentage SDS-PAGE gel was used (2.5% stacking gel, pH 6.8, and 3% separating gel, pH 8.8) without reduction. For fluorographic detection of radiolabeled protein, gels were equilibrated with Enhance® (New England Nuclear), vacuum-dried, and exposed to film (X-Omat AR Kodak) at −80 °C.

To measure the proportion of proα1(I) homotrimers secreted by the cells, ammonium sulfate precipitates of medium procollagens made by control cells, cells from an individual whose cells synthesized only homotrimers (resulting from homozygosity for a nonsense codon in COL1A2 (21)), and those made by cells from P2 were suspended in 0.5 M acetic acid and digested by pepsin (~0.1 mg/ml) overnight at 4 °C. After removal of insoluble material by centrifugation, pepsin-soluble collagen was precipitated by addition of NaCl to 0.9 M final concentration. The precipitate was collected by centrifugation and redissolved in 2 mM HCl, 0.03% Brij. Concentrations of normal control and homotrimer control collagens were evaluated by CD measurements on a J-810 spectropolarimeter (Jasco). Calibration mixtures of normal heterotrimmers and homotrimmers were prepared and compared with proband collagen by gel electrophoresis. Briefly, 10 μl of collagen solution (0.5–60 μg/ml) in 2 mM HCl was mixed with 2.5 μl of 0.5 M sodium carbonate/2.5 M NaCl, pH 9.3. Each sample was fluorescently labeled by addition of 0.5 μl of freshly prepared 10 mg/ml solution of Cy5 NHS ester (Amersham Biosciences) in anhydrous dimethylformamide followed by rapid mixing and incubation for 30 min at room temperature with gentle shaking. After labeling, each sample was mixed with 4× lithium deode- cyl sulfate sample loading buffer (Invitrogen), denatured by heating to 65 °C for several minutes and loaded into two lanes on a pre-cast 3–8% gradient Tris acetate gel (Invitrogen). After electrophoretic separation, each gel was rinsed for 30 min in 20% ethanol and scanned on an FLA5000 fluorescence scanner (Fuji Medical Systems) at 50-μm resolution. The gels were analyzed with the ScienceLab software supplied with the scanner. To ensure identical labeling conditions and optimal labeling intensity, all samples intended for comparison were adjusted to the same collagen concentration and labeled simultaneously using the same stock solution of Cy5. The concentration of the proband collagen solution was evaluated from the fluorescence intensity of the corresponding gel bands in a preceding calibration experiment.

Preparation of DNA and Mutation Characterization—Genomic DNA was prepared from cultured fibroblasts or blood using the QIAamp DNA Mini Kit (Qiagen). Total cellular RNA was isolated from cultured dermal fibroblasts using the RNeasy Mini Kit (Qiagen), and cDNA was made using the Superscript II First-Strand Synthesis System (Invitrogen). PCR products that span the COL1A1 and COL1A2 genes were screened for base mismatches by conformation sensitive gel electrophoresis (22), and the results were used to direct sequencing efforts. Mutant sequences were determined using the ABI Prism™ BigDye Terminator Cycle Sequencing Reaction Kit and the ABI Prism™ 310 Genetic Analyzer according to manufacturer’s recommendations (PerkinElmer Life Sciences), and the mutation identities were confirmed by sequencing opposite strands or by restriction endonuclease digestion. The primer sequences are available along with PCR conditions on request from the authors. Family members of P1 and P2 were screened for mutations by isolating genomic DNA from peripheral blood samples using the PureGene kit as recommended by the manufacturer (Gentra Systems), PCR, and sequencing as described above.

Immunocytochemistry—Procollagen accumulation in cultured dermal fibroblasts from P3 was evaluated by immunocytochemistry as described (23), with some minor changes. Briefly, cultured cells were washed with phosphate-buffered saline and treated with acetone/methanol (1:1) for 5 min at −20 °C. After three 5-min washes with Tris-buffered saline, cells were blocked with 2% goat and 0.5% horse sera (Jackson ImmunoResearch Laboratories) for 1 h. Fibroblasts were then incubated for 2 h with LF-116, a polyclonal antibody directed against the N-propeptide of proα2(I) (24), at a 1:40 dilution. The remaining steps were done as described (23).

RESULTS

Abnormal Type I Procollagen Was Made by Cultured Cells—Alterations in the amount of type I procollagen and the mobilities of the proα2(I) chains were subtle and differed among the four cell strains (Fig. 2). P1 cells made a population of proα2(I) chains, visible in the cell layer that migrated just above the normal chains. P2 cells made proα2(I) chains that migrated slightly faster than the normal chains. Following partial proteolysis with pepsin, the α2(I) chains in the medium and the cell layer migrated slightly faster than control and the α1(I) to α2(I) ratio was slightly altered (see below). P3 cells synthesized a population of proα2(I) chains with slowed mobility and following partial proteolysis with pepsin a distinct band that migrated more slowly than α2(I) was obvious in both the medium and the cell layer. The P4 cells also synthesized proα2(I) chains that had...
**Proα2(I) C-propeptide Is Necessary for Procollagen Assembly**

![Image](Image49x61to299x734)

**FIGURE 2.** Cells synthesized defective proα2(I) chains. Skin fibroblasts from a normal control individual (C) and P1–P4 were cultured, and proteins were metabolically labeled. Separation of collagenous proteins from cell and medium fractions by SDS-PAGE showed subtle alterations (indicated by arrows) in the amount of type I procollagen made and in the mobilities of the proα2(I) and α2(I) chains. P1 cells made chains, visible in the cell layer that migrated slowly. P2 cells made chains with faster mobilities. P3 cells synthesized chains with slower mobilities that were visible in all preparations. P4 cells made chains that had slow mobilities that were restricted to the cell layer.

slow mobilities and were located primarily in the cell layer. In contrast to the other cell strains, these cells appeared to secrete less type I procollagen than control cells without distinct retention of abnormal molecules.

**Mutations Were Located in the C-propeptide Coding Region of COL2A1**—We identified mutations in one COL2A2 allele in all four individuals (Fig. 3). In P1, a c.3944A → T transition in exon 51 predicted the substitution of aspartic acid by valine at position 1315 (D1315V), measured from the initiator methionine. All affected family members (Fig. 1) had the same mutation. In P2, insertion of a single nucleotide (c.3952_3953insT) in exon 51 resulted in a frameshift that substituted phenylalanine for the serine at position 1318 (S1318F) and created a premature termination codon (TAA) as the next downstream codon. This resulted in the deletion of 48 amino acids from the chain, including a cysteine involved in stabilizing the folded conformation of the chain. The mRNA from this allele was stable (data not shown). In P3, a c.3527G → T transversion in exon 50 predicted the substitution of glycine at position 1176 to valine (G1176V). P4 had a c.3487T → C transition that led to substitution by arginine for the first of the cysteines involved in interchain disulfide bonds (C1163R). The three missense mutations changed evolutionarily conserved amino acids and the frameshift mutation deleted several (Fig. 4).

**Type I Procollagen Assembly Was Hindered, and Proα2(I) Chains Accumulated Intracellularly**—The C-propeptides direct the initial assembly of proα chains into dimers and then into trimers. To see if molecular assembly was perturbed, we analyzed the kinetics of folding. Monomeric proα1(I) and proα2(I) chains were present in both control and patient cells (time 0, Fig. 5), and proα1(I) chains assembled into dimers and trimers by 20–40 min. In control cells excess proα2(I) chains present at time 0 left the monomeric pool by 60–80 min. In contrast, free proα2(I) chains were apparent in each patient cell strain for the duration of the chase period of 80 min.

Intracellular retention of proα2(I) chains was confirmed by immunolabeling cultured cells from a normal control and P3. Cells were stained with an antibody directed against the N-propeptide of proα2(I). Both normal and patient cells were stained in a pattern consistent with the presence of protein in the secretory pathway, but staining of P3 cells was markedly increased (Fig. 5).

**Proα1(I) Homotrimers Were Made**—Type I procollagen exists as two species: the major one has two proα1(I) chains and a single proα2(I) chain, but a minor population made in some tissues has three proα1(I) chains. Because chain-chain association is determined by sequences in the C-propeptides of proα chains, we examined the secreted procollagens to determine if any of the mutations resulted in failure of the abnormal proα2(I) chains to associate. The control cells made only heterotrimeric type I procollagen. Cells from two of the four individuals (P2 and P4) made significant amounts of proα1(I) homotrimer (Fig. 6a).

To determine the proportion of type I collagen that was made up of α1(I) trimers, we prepared mixtures of fluorescently labeled, hetero- and homotrimers and compared them by gel electrophoresis to similarly prepared P2 collagen (Fig. 6b–d). Based on the calibration curves (solid lines) built for the control mixtures of hetero- and homotrimers, homotrimers accounted for 25 ± 5% of the type I collagen secreted by the P2 cells, whether measured by comparing α1(I)/α2(I) ratios (Fig. 6c) or the proportion of cross-linked dimer species α1(I)–α1(I)/α1(I)–α2(I) (Fig. 6d).
Proα2(I) C-propeptide Is Necessary for Procollagen Assembly

FIGURE 4. Mutations changed conserved amino acid residues. The C-propeptide amino acid sequences of the 11 known proα chains were aligned. The chain selectivity domain (gray), cysteines, and intramolecular disulfide bonds are indicated. Residues that correspond to the single amino acid substitutions (P1, P3, and P4) are in bold font. The mutation of P2 deletes the terminal amino acids of the C-propeptide (indicated with dots). Each alteration involves residues that are completely conserved among the fibrillar collagen genes and, therefore, likely biologically important.

FIGURE 5. Defects hindered assembly of proα2(I) chains that accumulated intracellularly. Control (C) and patient (P1–P4) cells were pulse-labeled and then chased for up to 80 min. Control cells made proα2(I) monomers that gradually disappeared through time and were largely gone by 60–80 min, moving to the trimeric pool of molecules. The OI cells made proα2(I) chains that remained in the monomeric pool for the entire 80-min chase period. Immunofluorescence microscopy with an antibody against proα2(I) showed markedly increased intracellular levels of proα2(I) chains in the representative cell line, P3, relative to control cells.

DISCUSSION

The closely related proα chains of the fibrillar collagens are encoded by 11 homologous genes (COL1A1, COL1A2, COL2A1, COL3A1, COL5A1, COL5A2, COL5A3, COL11A1, COL11A2, COL24A1, and COL27A1) and assemble into trimeric molecules in a collagen type-specific manner. In some cells as many as six of these genes are co-expressed, and as a consequence, cells must organize the proα chains to the correct procollagen trimer in proper ratios. For type I procollagen, the predominant end-product of this assembly process comprises two proα1(I) chains and one proα2(I) chain, although small levels of proα1(I) homotrimers are also made in some tissues (25, 26). Other combinations of these chains have not been detected in tissue or in proteins from cultured cells but have been identified in cell-free systems that expressed only the recombinant C-propeptides of both type I procollagen proα chains (27).

The sequences that govern directed assembly reside in the C-propeptide domains of the proα chains. The propeptides can be looked at as having several domains: a proteolytic conversion site at which the BMP1 protein cleaves, an α-helical domain that precedes the first cysteine and may assist in trimerization and nucleation for triple helix formation (28), a set of four or three cysteine residues that are involved in interchain disulfide cross-link formation, a second set of four cysteine residues that stabilize the folded domain of each propeptide, and a region which, in contrast to each of the above, is not conserved among the chains and appears to function in specification of partners for each chain (Fig. 7). It has been suggested that molecular chaperones also play a role in correct assembly (27).

 Naturally occurring mutations have been identified in the gene that encodes the proα2(I) chains in humans (18), oim/oim mice (29), and dogs (30). All are symptomatic only in the homozygote, and the heterozygotes are reported to be clinically normal. In each case these are frameshift mutations that alter the last 48 amino acids (mouse and human) or the last 30 residues (dog) and eliminate the ability of the chains to associate with proα1(I) chains. As a consequence, only proα1(I) trimers are formed, and all have a moderately severe form of osteogenesis imperfecta. In each instance, the mRNA is stable so that the proteins are probably made but very rapidly degraded, although this last point has not been conclusively demonstrated. The phenotype has been generally attributed to the production of only proα1(I) trimers, but the identification of individuals with a form of Ehlers-Danlos syndrome whose cells make only proα1(I) trimers as a consequence of unstable COL1A2 mRNA (21) raises doubt about the proposed mechanism of pathogenesis. These findings suggest that, in part, cellular alterations from a high rate of proα2(I) destruction, presumably by the proteasome (31), may contribute to the phenotype.

The mutations we describe here are diverse and lead to varied effects on procollagen assembly (Fig. 7), but all result in a similar mild OI phenotype in the heterozygous individual. In two instances, for P1 and P2, the clinical picture, with some heterogeneity, is shared among individuals in several generations. P2 is most like the mutations previously reported in that it appears to dramatically decrease the inclusion of the altered chain into trimers. In those cells a frameshift results in synthesis of a truncated protein that appears to be very unstable and...
Pro\(\alpha 2(1)\) C-propeptide Is Necessary for Procollagen Assembly

**FIGURE 6.** Cells made pro\(\alpha 1(1)\) homotrimers. \(a\), proteins from the four cell lines (P1–P4) were separated on a low percentage gel to resolve hetero- and homotrimeric type I procollagen. Protein from normal cells that make only heterotrimers and from another cell line that makes only homotrimers were separated on the same gel as standards. All OI cells made heterotrimeric procollagen, but in addition, P2 and P4 synthesized and secreted pro\(\alpha 1(1)\) homotrimers (arrows). \(b\), to determine relative levels of homotrimers made by P2 cells, control mixtures of fluorescently labeled, pepsin-treated hetero- and homotrimeric proteins with known composition (0% and 50% homotrimer) were compared with a sample from P2 (c and d). These and other calibration mixtures (symbols) were used to generate a calibration curve (fitted solid line) by measuring the ratio of fluorescence intensities of either monomer or dimer bands. An average of measurements indicated that 25 ± 5% of the procollagen trimers made by P2 cells were homotrimeric. Each calibration mixture and the OI sample was separated into two samples and loaded into two gel lanes. An apparent single calibration point at a given concentration and a single dashed line for the monomer bands indicate identical measured fluorescent intensity ratios for the two samples. The homotrimer content was determined by comparison of the measured ratio with the corresponding fitted calibration curve. The labeling and measurements were repeated twice producing the same result for the homotrimer content in the proband.

FIGURE 6. Cells made pro\(\alpha 1(1)\) homotrimers. \(a\), proteins from the four cell lines (P1–P4) were separated on a low percentage gel to resolve hetero- and homotrimeric type I procollagen. Protein from normal cells that make only heterotrimers and from another cell line that makes only homotrimers were separated on the same gel as standards. All OI cells made heterotrimeric procollagen, but in addition, P2 and P4 synthesized and secreted pro\(\alpha 1(1)\) homotrimers (arrows). \(b\), to determine relative levels of homotrimers made by P2 cells, control mixtures of fluorescently labeled, pepsin-treated hetero- and homotrimeric proteins with known composition (0% and 50% homotrimer) were compared with a sample from P2 (c and d). These and other calibration mixtures (symbols) were used to generate a calibration curve (fitted solid line) by measuring the ratio of fluorescence intensities of either monomer or dimer bands. An average of measurements indicated that 25 ± 5% of the procollagen trimers made by P2 cells were homotrimeric. Each calibration mixture and the OI sample was separated into two samples and loaded into two gel lanes. An apparent single calibration point at a given concentration and a single dashed line for the monomer bands indicate identical measured fluorescent intensity ratios for the two samples. The homotrimer content was determined by comparison of the measured ratio with the corresponding fitted calibration curve. The labeling and measurements were repeated twice producing the same result for the homotrimer content in the proband.

poorly, if at all, incorporated into trimers. The truncation occurs just distal to the third of the four cysteine residues involved in stabilizing the intra-chain fold. Experimentally, deletion of the last 10 residues of the propeptide, which removes the last cysteine of the chain, stops chain association (32, 33). In cells from P2 the expectation would be that none of the abnormal pro\(\alpha 2(1)\) chains are incorporated into trimers. If this were correct, then the relative ratio of heterotrimer to homotrimer molecules should be ∼3:2, and the \(\alpha 1(1)\) to \(\alpha 2(1)\) ratio in intact molecules should be ∼4:1. Instead, we estimated the latter ratio to be closer to 3:1, which suggests that there is some incorporation of the abnormal chain or, alternatively, that there is excess pro\(\alpha 2(1)\) chains available for molecule heterotrimer generation. From the studies of the control cells in this report and studies by Chessler et al. (34) there appears to be an excess of pro\(\alpha 2(1)\) in cells that could compensate for failure of abnormal chains to incorporate into trimers.

Two other mutations we identified, D1315V in P1 and C1163R in P4, are also likely to alter disulfide bonding. C1163R results in substitution of arginine for the first cysteine in the propeptide. Experimental substitution of this residue by alanine in either the pro\(\alpha 2(1)\) chain or the pro\(\alpha 1(III)\) chain resulted in failure of trimer formation and of interchain disulfide bond formation (35). In cells from P4 it is clear that pro\(\alpha 2(1)\) chains are slow to incorporate into trimers and that pro\(\alpha 1(1)\) trimers form, reflecting the functional excess of those chains. The relative amount of the pro\(\alpha 1(1)\) trimers is less than in P2 suggesting that another factor may be at work. The relative amount of type I procollagen produced by those cells appears to be reduced compared with the control and the other OI cell strains. This suggests that the abnormal pro\(\alpha 2(1)\) chains could “capture” pro\(\alpha 1(1)\) chains during ineffective trimer formation and that those would then be degraded. In this individual, the phenotype could reflect the diminished amount of type I procollagen produced. The defect of P1 (D1315V) changes the charged aspartic acid residue to the branched hydrophobic residue valine, two amino acids N-terminal to one of the cysteine residues involved in intra-chain disulfide bond formation. This change could create a local hydrophobic pocket in which the cysteine could be hidden from access. Analysis of procollagens from the cells support this idea; they show an extra pro\(\alpha 2(1)\) band with decreased mobility, which could be caused by an extended, less compact formation, owing to failure of disulfide bond formation.

It appears that the G1176V substitution has an effect on helix formation similar to those seen by mutations within the helical domain itself, because overmodified \(\alpha 2(1)\) chains can be seen in both the medium and cell layer. This suggests that many of these chains are effectively incorporated into trimers, despite what appears to be a significant sequence change and, in contrast to some of the other mutations, allows helix to form, but apparently more slowly than normal so that additional modification occurs.

Unlike missense sequence alteration in the pro\(\alpha 1(1)\) C-propeptide, which often leads to lethal forms of OI, the pro\(\alpha 2(1)\) defects resulted in a relatively mild phenotype. The moderate severity probably reflects two factors. First, pro\(\alpha 1(1)\) chains can substitute for pro\(\alpha 2(1)\) chains in type I procollagen molecules (that is, pro\(\alpha 1(1)\) trimers) and thus could compensate for the loss of the chain. Further, pro\(\alpha 1(1)\) homotrimers are compatible with normal skeletal development and function (although when made, they can lead to skin and vessel abnormalities seen in forms of Ehlers-Danlos syndrome). Pro\(\alpha 2(1)\) cannot substitute for pro\(\alpha 1(1)\) chains, and so alterations in the amount or structure of those chains should be far more deleterious. Second, the pro\(\alpha 2(1)\) chain represents just one of three subunits in the fully assembled trimer, whereas the pro\(\alpha 1(1)\) chain occupies two of three positions. This means that, in the case of a pro\(\alpha 1(1)\) defect, three-quarters of possible trimers will...
have one or two defective chains: a proα2(I) defect will affect only half of the possible procollagen molecules.

Acknowledgments—We thank Russell J. Fernandes for valuable discussions concerning the work; Drs. Diane Broome, Virginia V. Michels, and Joan Stoler for referring the patients to us; and the patients for their kind cooperation.

REFERENCES

1. Byers, P. H., and Cole, W. G. (2002) Osteogenesis Imperfecta. In: Royce, P., and Steinmann, B. (eds), Connective Tissue and Its Heritable Disorders: Molecular, Genetic and Medical Aspects, 2nd Ed., Wylie
2. Myllyharju, J., and Kivirikko, K. I. (2001) Ann. Med. 33, 7–21
3. Lees, J. F., Tasab, M., and Bulleid, N. J. (1997) EMBO J. 16, 908–916
4. Dalgleish, R. (1997) Nucleic Acids Res. 25, 181–187
5. Dalgleish, R. (1998) Nucleic Acids Res. 26, 253–255
6. Raghunath, M., Bruckner, P., and Steinmann, B. (1994) J. Mol. Biol. 236, 940–949
7. Kivirikko, K. I., and Pihlajaniemi, T. (1998) Adv. Enzymol. Relat. Areas Mol. Biol. 72, 325–398
8. Vogel, B. E., Doelz, R., Kadler, K. E., Højima, Y., Engel, J., and Prockop, D. J. (1988) J. Biol. Chem. 263, 19249–19255
9. Forlino, A., Keene, D. R., Schmidt, K., and Marini, J. C. (1998) Matrix Biol. 17, 575–584
10. Vogel, B. E., Minor, R. R., Freund, M., and Prockop, D. J. (1987) J. Biol. Chem. 262, 14737–14744
11. Yang, W., Battineni, M. L., and Brodsky, B. (1997) Biochemistry 36, 6930–6935
12. Chessor, S. D., and Byers, P. H. (1993) J. Biol. Chem. 268, 18226–18233
13. Oliver, J. E., Thompson, E. M., Pope, F. M., and Nicholls, A. C. (1996) Hum. Mutat. 7, 318–326
14. Pace, J. M., Chitayat, D., Atkinson, M., Wilcox, W. R., Schwarze, U., and Byers, P. H. (2002) J. Med. Genet. 39, 23–30
15. Pace, J. M., Kuslich, C. D., Willing, M. C., and Byers, P. H. (2001) J. Med. Genet. 38, 443–449
16. Bateman, J. F., Lamande, S. R., Dahl, H. H., Chan, D., Mascara, T., and Cole, W. G. (1989) J. Biol. Chem. 264, 10960–10964
17. Willing, M. C., Cohn, D. H., and Byers, P. H. (1990) J. Clin. Invest. 85, 282–290
18. Pihlajaniemi, T., Dickson, L. A., Pope, F. M., Korhonen, V. R., Nicholls, A., Prockop, D. J., and Myers, J. C. (1984) J. Biol. Chem. 259, 12941–12944
19. Bonadio, J., and Byers, P. H. (1985) Nature 316, 363–366
20. Bonadio, J., Holbrook, K. A., Gelinias, R. E., Jacob, J., and Byers, P. H. (1985) J. Biol. Chem. 260, 1734–1742
21. Schwarze, U., Hata, R., McKusick, V. A., Shinkai, H., Høyne, H. E., Pyeritz, R. E., and Byers, P. H. (2004) Ann. Hum. Genet. 74, 917–930
22. Korkko, J., Annunen, S., Pihlajamaa, T., Prockop, D. J., and Ala-Kokko, L. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1681–1685
23. Chamberlain, J. R., Schwarze, U., Wang, P. R., Hira, R. K., Hankenson, K. D., Pace, J. M., Underwood, R. A., Song, K. M., Sussman, M., Prockop, D. J., and Russell, D. W. (2004) Science 303, 1198–1201
24. Fisher, L. W., Stubbs, J. T., 3rd, and Young, M. F. (1995) Acta Orthop. Scand. Suppl. 266, 61–65
25. Jimenez, S. A., Bashey, R. I., Benditt, M., and Yankowski, R. (1977) Biochem. Biophys. Res. Commun. 78, 1354–1361
26. Uitto, J. (1979) Arch. Biochem. Biophys. 192, 371–379
27. Alvares, K., Siddiqui, F., Malone, J., and Veis, A. (1999) Biochemistry 38, 5401–5411
28. McAlinden, A., Smith, T. A., Sandell, L. J., Ficheux, D., Parry, D. A., and Bulleid, N. J. (1998) J. Biol. Chem. 273, 23792–23798
29. Doyle, S. A., and Smith, B. D. (1998) J. Cell Biochem. 71, 233–242
30. Lim, A. L., Doyle, S. A., Balian, G., and Smith, B. D. (1998) J. Cell Biochem. 71, 216–232
31. Chessor, S. D., Wallis, G. A., and Byers, P. H. (1993) J. Biol. Chem. 268, 18218–18225
32. Cole, W. G. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7178–7182
33. Lim, A. L., Doyle, S. A., and Smith, B. D. (1998) J. Cell Biochem. 71, 216–232
34. Chessor, S. D., Wallis, G. A., and Byers, P. H. (1993) J. Biol. Chem. 268, 18218–18225
35. Lees, J. F., and Bulleid, N. J. (1994) J. Biol. Chem. 269, 24354–24360